格隆汇1月6日丨润达医疗(603108.SH)公布，根据《上海润达医疗科技股份有限公司章程》及相关法律 法规的规定，公司于近期召开公司第六届职工代表大会第四次会议，会议采用无记名投票方式审议通过 《关于选举公司第六届董事会职工董事的议案》，选举陆晓艳女士为公司第六届董事会职工董事，任期 与公司第六届董事会任期一致。 ...

格隆汇1月6日丨润达医疗(603108.SH)公布，根据《上海润达医疗科技股份有限公司章程》及相关法律 法规的规定，公司于近期召开公司第六届职工代表大会第四次会议，会议采用无记名投票方式审议通过 《关于选举公司第六届董事会职工董事的议案》，选举陆晓艳女士为公司第六届董事会职工董事，任期 与公司第六届董事会任期一致。 ...

Core Insights - The article emphasizes the shift in enterprises' understanding of "efficiency" from single-point tools to systematic and long-term foundational capability building in the context of digital transformation [1] - Deli Group, as a strategic partner of JD Enterprise, is leveraging its industry experience and continuous technological innovation to provide reliable and orderly basic office solutions for government and enterprise clients [1] Group 1: Company Overview - Deli Group, founded in 1981, has evolved into a global creative technology industry group, advocating for comprehensive solutions in various work and learning scenarios [4] - The company has diversified its offerings to include office supplies, stationery, tools, furniture, printers, children's educational products, and B2B services, achieving industry leadership in multiple segments [4][6] - Deli introduces over 5,000 new products annually and has received prestigious international design awards, showcasing its strong manufacturing and R&D capabilities [6] Group 2: Product Innovation - Deli has made significant investments in research and development since 2015, becoming the only domestic company with independent R&D and manufacturing capabilities for both inkjet printers and print heads [9] - The collaboration with Longxin has led to the launch of the "Longxin Shanyin" series, which utilizes 100% domestically produced main control chips to enhance printing security and cater to Chinese user habits [9][12] - Deli's multifunctional printers support automatic double-sided printing and high-speed output, reducing waiting times and saving approximately 50% in paper usage, contributing to a greener office process [12] Group 3: Strategic Collaboration - JD Enterprise plays a crucial role in connecting Deli with a vast array of quality enterprise clients, enhancing clarity and efficiency in product selection, procurement, delivery, and after-sales service [13] - Deli's enterprise business is projected to grow over 25% year-on-year by 2025, aided by JD Enterprise's support, as both companies deepen their collaboration to serve a broader range of government and enterprise clients [13] Group 4: Future Outlook - Deli aims to continue leveraging technological innovation to strengthen its manufacturing and R&D capabilities, providing more efficient, safe, and reliable products and solutions for government, commercial users, and consumers [14] - The company is committed to enhancing operational efficiency for organizations through orderly processes, aligning with the core logic of its sustained growth and competitive advantage [14]

| | | 上海润达医疗科技股份有限公司 可转债转股结果暨股份变动公告 二、可转债本次转股情况 公司本次发行的"润达转债"的转股期为 2020 年 12 月 23 日至 2026 年 6 月 16 日。 在 2025 年 10 月 1 日至 2025 年 12 月 31 日期间，共有人民币 38,000 元的"润 达转债"已转换成公司股份，转股数量为 2,927 股。截至 2025 年 12 月 31 日， 累计人民币 315,843,000 元的"润达转债"转换成公司股份，占可转债发行总量 57.4260%，累计转股数量为 24,144,672 股，占可转债转股前公司已发行股份总额 的 4.1662%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、可转债发行上市概况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 5 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-002 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 资产负债率为 | 70%以上的全资及控股子公司 | | | | | --- | --- | --- | --- | --- | | 担保对 | 被担保人名称 | | 杭州润达医疗管理有限公司 | | | | 本次担保金额 | 31,575 | 万元 | | | 象一 | 实际为其提供的担保余额 | 161,406.39 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担保对 | 被担保人名称 | | | 安徽泽芬生物科技有限公司 | | | ...

Group 1 - The core point of the news is that RunDa Medical's stock has increased by 5.02%, reaching a price of 15.70 yuan per share, with a trading volume of 329 million yuan and a turnover rate of 3.55%, resulting in a total market capitalization of 9.478 billion yuan [1] - RunDa Medical, established on January 6, 1999, and listed on May 27, 2015, is located in Shanghai and primarily provides in vitro diagnostic products and professional technical support to various medical laboratories through its comprehensive service system [1] - The company's main revenue composition includes reagents and other consumables at 93.50%, instruments at 3.70%, software development and services at 2.67%, and other supplementary sources at 0.14% [1] Group 2 - From the perspective of fund holdings, one fund under Dongcai has a significant position in RunDa Medical, with the Dongcai Vision Growth Mixed Fund A (018088) increasing its holdings by 21,600 shares in the third quarter, totaling 50,300 shares, which represents 4.81% of the fund's net value, making it the fifth-largest holding [2] - The Dongcai Vision Growth Mixed Fund A (018088) was established on April 11, 2023, with a latest scale of 12.0303 million yuan, achieving a year-to-date return of 28.7%, ranking 3300 out of 8155 in its category [2] - The fund manager, Sun Chenyang, has been in position for 2 years and 271 days, with the fund's total asset size at 33.8361 million yuan, achieving a best return of 38.97% and a worst return of -28.98% during his tenure [3]

Group 1 - The "14th Five-Year Plan" achievement exhibition showcases China's manufacturing capabilities, with Deli Group being the only stationery office enterprise invited to the National Museum of China, highlighting its self-developed writing products and printing technologies [1] - Deli Group has focused on overcoming technical challenges in the pen manufacturing sector, developing a core pen head system and self-researched ink to create adaptable solutions for various writing scenarios [3] - The company has made significant advancements in the printing technology sector, breaking through foreign monopolies by mastering four core printing technologies and becoming the only domestic enterprise with a complete product matrix in printing [5] Group 2 - Deli's participation in the National Museum reflects the progress of the Chinese stationery industry in upgrading its supply chain and achieving core technology independence, marking a shift from "Made in China" to "Created in China" [7] - The future of Chinese brands, driven by innovation, is expected to continue making breakthroughs in core areas, contributing to the momentum of "Chinese Intelligent Manufacturing" [9]

证券代码：603108 证券简称：润达医疗 公告编号：临2025-063 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 关于增加2025年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 因公司业务发展的需要，依据实际情况，增加与关联方2025年度日常关联交易预计的金额。 ● 本次日常关联交易不会导致公司对关联方形成依赖，不会影响上市公司的独立性。 ● 本次增加的日常关联交易金额在公司董事会审批范围之内，无需提交股东会审议。 一、增加日常关联交易履行的审议程序 2024年12月4日，公司第五届董事会第十九次会议审议通过了《关于公司2025年度日常关联交易预计的 议案》，关联董事回避表决。该议案经过公司2024年第三次临时股东大会审议通过，关联股东回避表 决。2025年内，公司经过第五届董事会第二十三次会议及第五届董事会第二十四次会议审议，分别通过 了《关于增加2025年度日常关联交易预计的议案》，关联董事回避表决。 2025年12月26日，公司第五届董事会 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-063 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于增加 2025 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因公司业务发展的需要，依据实际情况，增加与关联方2025年度日常关 联交易预计的金额。 本次日常关联交易不会导致公司对关联方形成依赖，不会影响上市公司 的独立性。 本次增加的日常关联交易金额在公司董事会审批范围之内，无需提交股 东会审议。 一、增加日常关联交易履行的审议程序 2024年12月4日，公司第五届董事会第十九次会议审议通过了《关于公司2025 年度日常关联交易预计的议案》，关联董事回避表决。该议案经过公司2024年第 三次临时股东大会审议通过，关联股东回避表决。2025年内，公司经过第五届董 事会第二十三次会议及第五届董事会第二十四次会议审议，分别通过了《关于增 加2025年度日常关联交易 ...

上海润达医疗科技股份有限公司 2026 年第一次临时股东会 会 议 材 料 【二零二五年十二月】 上海润达医疗科技股份有限公司 资料目录 一、2026年第一次临时股东会议程--------------------------------------------1 二、会议注意事项----------------------------------------------------------------------2 三、审议事项 1. 议案一：关于制定《董事、高级管理人员薪酬管理制度》的议案 ------------------------------------------------------------------------------------------3 2. 议案二：关于公司 2026 年度日常关联交易预计的议案--------------8 3. 议案三：关于选举非独立董事的议案--------------------------------------19 4. 议案四：关于选举独立董事的议案-----------------------------------------24 上 ...